|
|
Time |
Source |
|
Announcement
|
|
| 09 Jan 2020 |
12:22 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia to present at Biotech Showcase in San Francisco |
| 30 Dec 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
New number of shares and votes in Oasmia Pharmaceutical AB (publ) |
| |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019 |
| 09 Dec 2019 |
5:50 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Final result of the rights issue in Oasmia |
| 06 Dec 2019 |
11:25 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia’s rights issue has been oversubscribed |
| 27 Nov 2019 |
8:16 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue |
| |
5:04 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue |
| 19 Nov 2019 |
12:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus |
| 18 Nov 2019 |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia invites to investor meetings in connection to the rights issue |
| 11 Nov 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia resolves on a rights issue of approximately SEK 399 million |
| 06 Nov 2019 |
3:35 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019 |
| 14 Oct 2019 |
7:48 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB |
| |
7:46 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million |
| 26 Sep 2019 |
6:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019 |
| |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019 |
| 18 Sep 2019 |
7:45 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte |
| |
7:20 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia presents Q1 report through audiocast on September 26 |
| 15 Sep 2019 |
8:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019 |
| 05 Sep 2019 |
2:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability |
| 04 Sep 2019 |
8:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia completes its management team |
| 28 Aug 2019 |
10:15 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Notice of Annual General Meeting in Oasmia Pharmaceutical AB |
| 27 Aug 2019 |
2:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia updates regarding MGC disputes |
| 23 Aug 2019 |
9:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia ADSs delisted from NASDAQ in the US |
| 20 Aug 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Nomination committee in Oasmia for the 2019 AGM |
| 15 Aug 2019 |
1:30 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar |
| 02 Aug 2019 |
4:40 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs |
| 31 Jul 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
New number of shares and votes in Oasmia Pharmaceutical AB (publ) |
| 09 Jul 2019 |
11:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia discontinues cooperation with former executive chairman |
| 05 Jul 2019 |
12:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia |
| 04 Jul 2019 |
8:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia appoints Business Advisory Board |
| 02 Jul 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia appoints Scientific Advisory Board |
| |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia appoints new CMO |
| 28 Jun 2019 |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia announces change of CEO |
| |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner |
| |
6:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019 |
| 26 Jun 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia presents full-year report and status in the Board's review through audiocast on June 28 |
| 25 Jun 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Two studies finalized in Oasmia Pharmaceutical’s Docecal programme |
| 15 May 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia postpones the release of the Q4 and year-end report to 28 June |
| 10 Apr 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia expands the Management Team |
| 03 Apr 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Short report of the status of the review in Oasmia |
| 28 Mar 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”. |
| 26 Mar 2019 |
12:00 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Notification from Oasmia Pharmaceutical AB |
| |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
CFO of Oasmia, Anders Blom has resigned |
| 25 Mar 2019 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information |
| 21 Mar 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
New Board starts reviewing the situation in Oasmia |
| 19 Mar 2019 |
9:30 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019 |
| 18 Mar 2019 |
3:10 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia announces a prospectus regarding admission to trading of new shares |
| 06 Mar 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical Strengthens its Management Team and Organization |
| 04 Mar 2019 |
7:49 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia has completed a directed share issue of approximately 165 MSEK |
| 01 Mar 2019 |
7:15 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ) |
| 05 Feb 2019 |
9:50 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) - UPDATED VERSION |
| |
9:32 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) |
| 31 Jan 2019 |
9:05 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) |
| 22 Jan 2019 |
9:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019 |
| 21 Jan 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled |
| 15 Jan 2019 |
7:30 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information |
| 17 Dec 2018 |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting |
| 14 Dec 2018 |
4:40 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) |
| 30 Nov 2018 |
9:30 pm |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) |
| |
7:00 am |
GNW
|
|
|
Oasmia Pharmaceutical AB (0N4A) |
Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018 |